Your browser is no longer supported. Please, upgrade your browser.
BNTX BioNTech SE monthly Stock Chart
BNTX [NASD]
BioNTech SE
Index- P/E- EPS (ttm)- Insider Own1.18% Shs Outstand238.67M Perf Week19.38%
Market Cap28.55B Forward P/E7.45 EPS next Y16.68 Insider Trans0.00% Shs Float223.06M Perf Month46.49%
Income- PEG- EPS next Q0.09 Inst Own10.40% Short Float2.77% Perf Quarter102.84%
Sales- P/S- EPS this Y-300.50% Inst Trans-8.28% Short Ratio1.97 Perf Half Y137.19%
Book/sh4.63 P/B26.83 EPS next Y1344.00% ROA- Target Price105.32 Perf Year465.24%
Cash/sh5.23 P/C23.77 EPS next 5Y- ROE- 52W Range20.72 - 115.00 Perf YTD266.71%
Dividend- P/FCF- EPS past 5Y- ROI-31.40% 52W High8.03% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low499.61% ATR7.78
Employees1800 Current Ratio4.10 Sales Q/Q-47.10% Oper. Margin- RSI (14)69.68 Volatility6.69% 6.28%
OptionableYes Debt/Eq0.33 EPS Q/Q-314.60% Profit Margin- Rel Volume3.13 Prev Close109.99
ShortableYes LT Debt/Eq0.19 EarningsNov 10 BMO Payout- Avg Volume3.14M Price124.24
Recom2.20 SMA2026.76% SMA5042.29% SMA20093.09% Volume9,823,552 Change12.96%
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Nov-04-19Initiated BofA/Merrill Buy $21
Nov-04-19Initiated Berenberg Buy $25
Nov-30-20 11:03PM  
05:33PM  
05:05PM  
04:54PM  
04:49PM  
04:31PM  
02:25PM  
12:54PM  
12:27PM  
12:18PM  
10:34AM  
10:18AM  
07:00AM  
06:29AM  
Nov-29-20 05:02PM  
10:10AM  
Nov-27-20 04:38PM  
01:27PM  
01:10PM  
11:06AM  
10:05AM  
09:21AM  
08:39AM  
07:45AM  
Nov-26-20 09:28AM  
Nov-25-20 05:30PM  
04:28PM  
04:17PM  
12:48PM  
11:49AM  
11:25AM  
10:35AM  
10:16AM  
09:49AM  
08:36AM  
07:45AM  
06:00AM  
Nov-24-20 01:36PM  
12:10PM  
12:05PM  
11:44AM  
11:04AM  
10:53AM  
09:21AM  
09:00AM  
06:31AM  
04:57AM  
Nov-23-20 06:28PM  
06:00PM  
05:40PM  
05:17PM  
04:13PM  
10:59AM  
10:59AM  
09:23AM  
08:48AM  
08:33AM  
08:18AM  
08:00AM  
07:45AM  
05:40AM  
Nov-22-20 11:31AM  
08:30AM  
06:53AM  
06:20AM  
06:11AM  
Nov-21-20 05:30PM  
02:30PM  
10:00AM  
Nov-20-20 04:45PM  
04:17PM  
04:15PM  
02:38PM  
01:04PM  
12:20PM  
11:46AM  
11:25AM  
11:24AM  
10:15AM  
10:06AM  
09:59AM  
09:54AM  
09:37AM  
09:22AM  
08:36AM  
08:27AM  
07:55AM  
07:44AM  
07:19AM  
07:03AM  
06:58AM  
06:52AM  
06:45AM  
05:30AM  
01:46AM  
01:04AM  
Nov-19-20 09:49PM  
07:48PM  
05:39PM  
04:36PM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.